stockrowXenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
Follow XENE
Alert me
Xenon Pharmaceuticals Inc. (XENE) Revenue
Xenon Pharmaceuticals Inc.'s revenue for fiscal 2025 was $7.5M, down 20.5% from $9.4M in fiscal 2022. Over the past ten years it has ranged from $311.0K (fiscal 2017) to $32.2M (fiscal 2020); the current reading is higher than 50% of that period. Revenue has fallen for 3 consecutive fiscal years. Xenon Pharmaceuticals Inc. ranks 190th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $7.5M | (20.50%) |
| FY2022 | $9.4M | (48.83%) |
| FY2021 | $18.4M | (42.68%) |
| FY2020 | $32.2M | 371.02% |
| FY2019 | $6.8M | 2,095.82% |
| FY2017 | $311.0K | (82.75%) |
| FY2016 | $1.8M | (88.43%) |
| FY2015 | $15.6M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Mar 2025 | $7.5M | 5,581.82% |
| Sep 2022 | $132.0K | (75.37%) |
| Jun 2022 | $536.0K | (93.89%) |
| Mar 2022 | $8.8M | 134.57% |
| 22 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $1.2B |
| IOVA Iovance Biotherapeutics, Inc. compare | $379.0M |
| ABCL AbCellera Biologics Inc. compare | $66.2M |
| TNGX Tango Therapeutics, Inc. compare | $62.4M |
| XENE Xenon Pharmaceuticals Inc. | $16.9M |
| RLAY Relay Therapeutics, Inc. compare | $11.0M |
| VKTX Viking Therapeutics, Inc. compare | — |
| PBLS Parabilis Medicines, Inc. compare | — |
| IRON Disc Medicine, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on XENE
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement